Osimertinib, platinum, and etoposide for patients with metastatic EGFR/TP53/RB1-mutant lung cancers at risk for histological transformation.
Although EGFR inhibitors are highly effective for treating EGFR-mutant lung adenocarcinomas (EGFR+ LUADs), resistance inevitably emerges, with histologic transformation to small cell lung cancer (SCLC) representing a particularly aggressive mechanism. Our prospective trial enrolled patients with EGFR+ LUAD at high risk...